RE:RE:RE:February Presentation MM used the Spectral EBITDA numbers from the February presentation (as did I). When you study it they show (for the 40% case) 56,000 patients and 112,000 PMX columns at $7,500 per column or approx $840 million revenue. On that gross revenue they show Spectral EBITDA of $235 million. All amounts USD. Baxter would be in the $605 million of costs between revenue and Spectral's EBITDA.
Based on the numbers Baxter and all other costs are 72% of revenue. No breakdown was provided for the 72%. Would be very happy if they provided that. I doubt that Toray, Birch Hill, the Alberta80, management and lastly shareholders would allow a CCAA filing for a company within spitting distance of these riches. Before that happened Baxter would snap it up anyway IMO.